Attention Deficit Hyperactivity Disorder Subtypes and Symptom Response in Adults Treated With Lisdexamfetamine Dimesylate

by Greg Mattingly, MD; Richard Weisler, MD; Bryan Dirks, MD; Thomas Babcock, DO; Ben Adeyi, MS; Brian Scheckner, PharmD; and Robert Lasser, MD
Dr. Mattingly is from Washington University School of Medicine in St. Charles, Missouri; Dr. Weisler is from Duke University Medical Center in Durham, North Carolina, and the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Drs. Dirks, Babcock Scheckner, and Lasser and Mr. Adeyi are from Shire Development LLC, Wayne, Pennsylvania.

Innov Clin Neurosci. 2012;9(5–6):22–30

Tags: adults; ADHD-RS-IV symptom subtype; amphetamine; stimulant; predominantly inattention; predominantly hyperactivity/ impulsivity; predominantly combined; clinical response, Lisdexamfetamine dimesylate (LDX); attention-deficit/hyperactivity disorder (ADHD)

Category: Attention Deficit Hyperactivity Disorder, Original Research, Psychiatry